United Therapeutics insiders sell shares worth over $9 million

Chief Executive Officer Martine Rothblatt sold 9,500 shares of United Therapeutics stock on May 18 at an average price of $567.04, generating proceeds of about $5.39 million. Executive Vice President Paul Mahon sold 8,300 shares on May 21 at an average price of $562.82, yielding roughly $4.67 million. Following the transactions, Rothblatt’s and Mahon’s holdings in the company were reduced, with Mahon retaining 45,172 shares valued at approximately $25.42 million.